Skip to main
RCEL

RCEL Stock Forecast & Price Target

RCEL Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AVITA Medical is a positive potential investment due to its innovative one-product RECELL system that speeds up the burn treatment process, leading to reduced healthcare costs and increased patient satisfaction. The recent contract with BARDA and expanding wound care portfolio also bode well for the company's future growth and market share. Furthermore, AVITA has a strong cash position and continues to improve its financials, making it a promising opportunity in the healthcare sector.

Bears say

AVITA Medical is a largely single product company with limited international expansion and over reliance on the US market. Despite reported increases in revenue in 2025, the company has faced disruption in reimbursement and operational stabilization, and future growth is largely execution-dependent. A lower operating cost base and new revenue guidance suggest potential for future growth, but a lack of diversification and reliance on a single product remains a concern.

RCEL has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AVITA Medical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AVITA Medical Inc (RCEL) Forecast

Analysts have given RCEL a Strong Buy based on their latest research and market trends.

According to 3 analysts, RCEL has a Strong Buy consensus rating as of Jun 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AVITA Medical Inc (RCEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.